Novartis (France)

Recent papers from Novartis (France)

1. Effectiveness of Rimegepant for the Acute Treatment of Migraine Among Participants Using Different Types of Preventive Therapy: Analyses from CONFIDENCENeurology and Therapy · 2026
2. Identifying barriers to lipoprotein(a) testing in secondary cardiovascular prevention and co-designing implementation strategies: an Italian behavior change wheel-informed studyFrontiers in Cardiovascular Medicine · 2026
3. Real-World Outcomes of [ ¹⁷⁷ Lu]Lu-PSMA-617 in the French Early-Access Program for Patients with Metastatic Castration-Resistant Prostate CancerJournal of Nuclear Medicine · 2026
4. Unmet needs and quality of life burden in chronic myeloid leukemia: results from a nationwide Italian real-world surveyFrontiers in Oncology · 2026
5. Consistency of response to rimegepant for the acute treatment of migraine among real-world users – findings from the prospective observational CONFIDENCE studyThe Journal of Headache and Pain · 2026
6. Nonlinear dimensionality reduction through optimal transport between incomparable spacesInformation Geometry · 2026
7. Simulation der Auswirkungen eines edukativen und digitalen Ansatzes unter Verwendung von Patient‐Journey‐Modellen, um praktische Herausforderungen bei der Behandlung der chronischen spontanen Urtikaria in Deutschland zu bewältigenJDDG Journal der Deutschen Dermatologischen Gesellschaft · 2026
8. Results from a French brolucizumab access program for pretreated patients with neovascular age-related macular degeneration.2026
9. Ruxolitinib in treatment-naive or corticosteroid-refractory pediatric patients with chronic graft-versus-host disease: final analysis of the phase 2 REACH5 trialHaematologica · 2026
10. Abstract PS3-08-27: Repower: a real-world noninterventional study of outcomes and experiences in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) early breast cancer (EBC) treated with an adjuvant cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) plus endocrine therapy (ET)Clinical Cancer Research · 2026
11. Prevalence of elevated lipoprotein(a) in premature ASCVD patients and its association with major adverse cardiovascular events: analysis of a large US electronic health record databaseEuropean Heart Journal · 2025
12. Association of elevated lipoprotein(a) with future major adverse cardiovascular events in recurrent ASCVD patients: analysis of a large US electronic health record databaseEuropean Heart Journal · 2025
13. How to differentiate between clinical added value (CAV) V drugs: What are the implications, and what is the access pathway?Therapies · 2025
14. Comment discriminer les médicaments d’ASMR V : quelles implications et quel parcours d’accès ?Therapies · 2025
15. Reimagining medical affairs through strategic leadership in patient partnering healthcareDrug Discovery Today · 2025
16. [A Report on Health Resource Use in Internal Radiation Therapy Using Lutetium-177 (2025
17. Mechanism of SK2 channel gating and its modulation by the bee toxin apamin and small molecules2025
18. [Evaluation of Appropriate Treatment Infrastructure for Radionuclide Therapy Through Discrete Event Simulation].2025
19. Creating and maintaining corporate culture in a multinational organisation˜The œbusiness & management collection. · 2025
20. Specificity and exon target space of splicing modifying compounds2025